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Aryl hydrocarbon receptor-microRNA-212/
132 axis in human breast cancer
suppresses metastasis by targeting SOX4
Hamza Hanieh
Abstract
Background: MicroRNAs (miRNAs) are a class of short non-coding RNAs that pave a new avenue for understanding
immune responses and cancer progression. Although the miRNAs are involved in breast cancer development, their
axis with the transcription factors that show therapeutic potential in breast cancer is largely unknown. Previous
studies showed anti-metastatic roles of agonist-activated aryl hydrocarbon receptor (Ahr) in various breast cancer
cell lines. Recently, we demonstrated that agonist-activated Ahr induced a highly conserved miRNA cluster, named
miR-212/132, in murine cellular immune compartment. Therefore, current study was performed to examine if this
miRNA cluster mediates the anti-metastatic properties of Ahr agonists.
Methods: The expression of miR-212/132 cluster and coding genes were examined by real-time PCR, and the protein
levels were detected by western blot. The 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and 3,3′-diindolylmethane (DIM)
were used to activate Ahr in MDA-MB-231 and T47D breast cancer cells. Chromatin immunoprecipitation (ChIP) assay
was used to identify the binding site(s) for Ahr on miR-212/132 promoter. For prediction of potentially target gene of
the miRNA cluster, bioinformatics analysis was carried out, and to test targeting, luciferase activity was quantified.
Besides, biological effects of Ahr-miR-212/132 axis were examined in vitro by cell migration, expansion and invasion,
and examined in vivo by orthotopic model of spontaneous metastasis.
Results: The miR-212/132 cluster was transcriptionally activated in MDA-MB-231 and T47D cells by TCDD and DIM, and
this activation was regulated by Ahr. A reciprocal correlation was identified between Ahr agonists-induced miR-212/132
and the pro-metastatic SRY-related HMG-box4 (SOX4), and a new specific binding sites for miR-212/132 were identified
on the untranslated region (3′UTR) of SOX4. Interestingly, miR-212/132 over-expression showed direct anti-migration,
anti-expansion and anti-invasion properties, and an inhibition of the miRNA cluster mitigated the anti-invasive properties
of TCDD and DIM. Further in vivo studies demonstrated that the Ahr-miR-212/132-SOX4 module was induced by Ahr
activation.
Conclusion: Taken together, the findings provide the first evidences of the synergistic anti-metastatic properties of
miR-212/132 cluster through suppression of SOX4. Also, current study suggest a new miRNA-based mechanism
elucidating the anti-metastatic properties of Ahr agonists, suggesting possibility of using miR-212/132 to control
metastasis in breast cancer patients.
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Introduction
Breast cancer is the most common cause of cancer-
associated deaths amongst women in developed and de-
veloping countries [1]. Metastasis, the spread of a tumor
to distant organs, accounts for 90 % of breast cancer pa-
tients’ mortality [2]. Important advances have been
achieved to understand the complicated process of me-
tastasis, and various molecules have shown promising
anti-metastatic properties [3–5]. However, detailed
mechanisms remain to be defined.
The microRNAs (miRNAs) are small non-coding RNAs
of ∼ 22 nt that regulate gene expression at the post-
transcriptional level. These molecules add a new dimen-
sion for understanding cancer progression. An increasing
paradigm has clearly shown that miRNAs are involved in
breast cancer metastasis. For example, miR-10b promotes
breast cancer cell invasion and metastasis by targeting
syndecan-1 (SDC1) in MDA-MB-231 and MCF-7 cells
[6]. The invasion of MDA-MB-231 and BT-20 cells is di-
minished by over-expression of c-Met-targeting miR-335
[7]. Furthermore, miR-135 and miR-203 reduce tumor
growth and metastasis of MD-MB-231 cells to the
bones by targeting the runt-related transcription factor
2 (Runx2) [8].
MiR-212 and miR-132 are tandem miRNAs at the same
location on chromosome 17 in humans, called miR-212/
132 cluster, and they share the same seed sequence and
the transcriptional regulatory elements. Extensive studies
have revealed important roles of this miRNA cluster in
the different body systems, which may suggest potential
therapeutic strategy. For example, miR-212/132 cluster is
involved in mammary gland development [9, 10], neuronal
differentiation and cognitive processes [11–13], cardiac
hypertrophy and cardiomyocyte autophagy [14], auto-
immune inflammation [15], vasodilatory function and an-
giogenic responses [16].
In breast cancer, miR-132 suppresses cell proliferation,
invasion, migration and metastasis of different breast can-
cer cells through direct suppression of hematological and
neurological expressed 1 (HN1) [17]. Over-expression of
this miRNA suppresses proliferation and colony formation
of MDA-MB-231 and MCF-7 [18]. Moreover, miR-132
causes expression changes of genes involved in metabol-
ism, DNA damage and cell motility in immortalized fibro-
blasts co-cultured with epithelial columnar cell hyperplasia
(CCH) cells [19]. Although the role of miR-212 has been
investigated in different cancer types [20, 21], it has never
been investigated alone or in a combination with miR-132
in breast cancer.
The aryl hydrocarbon receptor (Ahr) is an environmen-
tally responsive transcription factor activated by structurally
diverse agonists see [22]. It is demonstrated that the Ahr-
active omeprazole decreases invasion and metastasis in es-
trogen receptor (ER)-negative breast cancer cell lines by
down-regulation of matrix metalloproteinase-9 (MMP-9)
and C-X-C chemokine receptor 4 (CXCR4) [23]. Activation
of Ahr by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and
6-methyl-1,3,-trichlorodibenzofuran (MCDF) suppresses
metastasis of ER-negative breast cancer cells to the lungs
[24, 25]. Zhang and colleagues [25] suggest that both
TCDD and MCDF induce miR-335 targeting the pro-
metastatic mediator SRY-related HMG-box4 (SOX4).
However, no more studies were performed to provide more
miRNA-based mechanistic explanations.
Activation of Ahr by 3,3′-diindolylmethane (DIM) sup-
presses breast cancer through repression of CXCR4 and/or
CXCL12, and thereby, lowering the invasive and metastatic
potential of MDA-MB-231 and MCF-7 cell [26]. In ER-
negative breast cancer cell lines, DIM suppresses cell pro-
liferation and motility of MDA-MB-231 by inhibition of
phosphorylation of hepatocyte growth factor (HGF) and c-
Met at the tyrosines residues [27]. Furthermore, oral treat-
ment of DIM inhibits metastasis of 4T1 cells accompanied
by reduced levels of MMP, adhesion molecules, and pro-
inflammatory cytokines [28]. Importantly, the underlying
mechanisms of the anti-cancer activities of DIM are not
simply attributed to the Ahr since DIM is a relatively weak
agonist. For example, the DIM inhibits carcinogen-
induced mammary tumor growth in Sprague–Dawley
rats and this is not concomitant with the hepatic
CYP1A1-dependent activity [29]. In addition, no stud-
ies have investigated the involvement of miRNAs in the
anti-metastatic effect of DIM.
In recent studies, we found that TCDD and 6-
formylindolo[3,2-b]carbazole (FICZ) induced the highly
conserved miR-212/132 cluster in the murine cellular
immune compartment [15, 30]. Therefore, it was hy-
pothesized here that the miR-212/132 cluster may be
induced in human breast cancer cells by Ahr agonists,
and may contribute to their anti-metastatic properties.
Thus, the effects of TCDD and DIM on miR-212/132
expression and metastatic features in human breast
cancer cells were investigated. The current results, for
the first time, demonstrated that toxic and non-toxic
Ahr agonists suppressed breast cancer metastasis
through triggering the transcription of SOX4-targeting
miR-212/132 cluster. It was further shown that miR-
212/132 cluster is a metastasis suppressor in breast
cancer cells.
Results
TCDD and DIM suppress motility of breast cancer cells in
an Ahr-dependent fashion
A wound healing assay was used to examine the effects
of TCDD and DIM on migration of MDA-MB-231 and
proliferation-based expansion of T47D. The TCDD
(10 nmol/L) and DIM (25 μmol/L) suppressed cell mi-
gration of MDA-MB-231, whereas the expansion of
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T47D was inhibited by DIM only (Fig. 1a). Inhibition of
Ahr using silencing RNA (siAhr) blocked the effect of
TCDD on the migration of MDA-MB-231 cells, while
partially inhibited the anti-expansion effect of DIM on
both cell lines (Additional file 1: Figure S1), suggesting an
Ahr-independent effects of DIM. No significant effects
were observed on the proliferation of MDA-MB-231 cells
with TCDD (1–25 nmolL) or DIM (10–50 μmol/L) treat-
ments (Additional file 1: Figure S2A). The DIM, but not
TCDD, suppressed the proliferation of T47D and adhesion
of T47D and MD-MB-231 in a concentration-dependent
fashion (Additional file 1: Figure S2B and C). The inhibi-
tory effects of DIM on proliferation and adhesion of T47D
might have contributed to the suppressive effect of DIM
on cell expansion in wound healing. To further assess the
effects of Ahr agonists on motility of breast cancer cells,
cell invasion was examined by Boyden chamber assay. The
results in Fig. 1b and c show that TCDD (10–25 nmol/L)
and DIM (10–50 μmol/L) significantly decreased cell inva-
sion of MD-MB-231, whereas the invasion of T47D cells
was decreased by DIM only (10–50 μmol/L).
The role of Ahr in mediating the inhibitory effects of
TCDD and DIM on the invasion of breast cancer cells
was investigated by inhibition of Ahr using silencing RNA
(siAhr). Transfection of siAhr drastically decreased Ahr
gene expression compared with non-specific nucleotides
(siNS)-transfected controls of MDA-MB-231 and T47D
(Fig. 1d). Knockdown of Ahr abrogated the inhibitory ef-
fects of TCDD (10 nmol/L) and DIM (25 μmol/L) on in-
vasion of MDA-MB-231 and T47D cells (Fig. 1e), showing
that Ahr mediated the agonists-suppressed invasion of
breast cancer cells. Activation of Ahr by TCDD and DIM
was confirmed by the quantification of CYP1A1 gene ex-
pression (Fig. 1f).
Agonist-activated Ahr regulates miR-212/132 expression
in breast cancer cells
To examine the hypothesis of Ahr-miR-212/132 axis in
breast cancer cells, the expression of miR-212/132 clus-
ter was measured by real-time PCR. Both TCDD
(10 nmol/L) and DIM (25 μmol/L) induced the miRNAs
cluster in MDA-MB-231 and T47D in 24 h after treat-
ment (Additional file 1: Figure S3A). However, the ex-
pression of the miRNA cluster peaked with less
standard deviation at 48 h after TCDD (1–25 nmol/L)
and DIM (10–50 μmol/L) treatments in both cell lines
(Fig. 2a). To support these findings, two more Ahr-
specific agonists were used to examine their effects on the
miR-212/132 cluster expression. Activation of Ahr by 2-
(1′H-indole-3′-carbonyl)-thiazole-4-carboxylic acid me-
thyl ester (ITE; 100 nmol/L) and 3-methylcholanthrene
(3MC; 1 μmol/L) induced the expression of miRNA clus-
ter in MDA-MB-231 and T47D at 48 h after treatment
(Additional file 1: Figure S3B). These results suggested
that the agonist-activated Ahr was involved in up-
regulation of miR-212/132 in both breast cancer cell lines.
To investigate whether Ahr was directly involved in
miR-212/132 expression, first, Ahr was inhibited by RNA
interference. Results illustrated in Fig. 2b show that siAhr
blocked the Ahr agonist-induced miR-212/132 cluster. To
further test a direct regulatory role of Ahr, 1 kb of miR-
212/132 promoter was analyzed for the xenobiotic respon-
sive elements (XRE) using transcription factor prediction
software. i.e., Promo V3.0.2 [31]. Binding activity of Ahr to
the two xenobiotic responsive elements (XRE) located
within 1 kb in the promoter of miR-212/132 gene were ex-
amined by Chromatin immunoprecipitation (ChIP) assay.
The Ahr physically bound to the XRE-2 located at 830 bp
from miR-212/132 transcription site (Fig. 2c). Binding of
Ahr to the XRE box of a well-known responsive gene
CYP1A1 was used as positive control. Finally, luciferase
activity was quantified in breast cancer cells co-
transfected with miR-212/132 promoter reporter and
siAhr. Knockdown of Ahr in Ahr agonists-treated cells
significantly inhibited the luciferase activity driven by
miR-212/132 promoter (Fig. 2d). Collectively, the results
demonstrated for the first time that Ahr directly regulated
miR-212/132 transcription by functional binding on miR-
212/132 promoter.
MiR-212/132 has a direct inhibitory role on motility of
breast cancer cells
To study whether the miR-212/132 cluster has a direct
role on motility of breast cancer cells, the cluster mimics
were transfected separately into MDA-MB-231 and T47D
cells. Over-expression of miR-132 and miR-212 showed
inhibitory effects on migration of MDA-MB-231 and ex-
pansion of T47D cells in wound healing assay, and inva-
sion in Boyden chamber in both cell lines compared with
siNS-transfected controls (Fig. 3a and b). Consistently, in-
hibition of the miRNA cluster by transfection of antisense
(as-) into the TCDD- or DIM-treated breast cancer cells
mitigated the agonists’ inhibitory effects on invasion of
MDA-MB-231 and T47D (Fig. 3c), suggesting a direct in-
hibitory role of miR-212/132 on motility of MDA-MB-231
and T47D cells. Efficiency of miR-212/132 inhibition by
antisense was confirmed by real-time-PCR as shown in
Fig. 3d.
TCDD and DIM down-regulate SOX4 in breast cancer cells
by triggering Ahr-miR-212/132 axis
The effects of TCDD and DIM on gene expression of the
pro-metastatic factor SOX4 were examined by real-time
PCR and western blot. Both TCDD and DIM significantly
down-regulated SOX4 gene expression in MDA-MB-231
and T47D cells (Fig. 4a). Conversely, inhibition of Ahr by
siAhr restored the Ahr agonists-suppressed SOX4 in both
cell lines (Fig. 4b), suggesting that TCDD and DIM down-
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Fig. 1 (See legend on next page.)
Hanieh Molecular Cancer  (2015) 14:172 Page 4 of 13
Fig. 2 TCDD and DIM induce miR-212/132 cluster in breast cancer cells in an Ahr-dependent fashion. a TCDD (1–25 nmol/L) and DIM
(10–50 μmol/L) induced miR-212/132 cluster in MDA-MB-231 and T47D cells, miRNA expression was quantified by real-time PCR. b siAhr
blocked the 10 nmol/L TCDD- and 25 μmol/L DIM-induced miR-212/132 expression in MDA-MB-231 and T47D cells compared with the
siNS-transfected control. c ChIP assay analysis of Ahr binding activity on XRE box on upstream sequence of miR-212/132 gene. The breast
cancer cells were treated with 10 nmol/L TCDD or 25 μmol/L DIM for 24 h. Presented is XRE-2 that showed interaction with Ahr. d siAhr
suppressed the luciferase activity of miR-212/132 promoter reporter. Data are shown as mean ± SD of three independent experiments
performed in triplicates. a *P < 0.05, significantly different from DMSO-treated control. b and d *P < 0.05, significantly different from
DMSO-treated control or Ahr agonist- and siAhr-treatments
(See figure on previous page.)
Fig. 1 TCDD and DIM inhibit motility of breast cancer cells in vitro in an Ahr-dependent fashion. a The inhibitory effects of 10 nmol/L TCDD or 25 μmol/L
DIM on migration of MDA-MB-231 and expansion of T47D cells were examined by wound healing assay. b Cell invasion of MDA-MB-231 was suppressed
by TCDD (10–25 nmol/L) and DIM (10–50 μmol/L) in the Boyden chamber assay. c DIM (10–25 μmol/L), but not TCDD, inhibited the invasion of T47D
cells. d Efficiency of Ahr knockdown by siAhr compared with siNS was confirmed by real-time PCR and western blot. e siAhr abrogated the inhibitory
effects of TCDD and DIM on the invasion of MDA-MB-231 and T47D cells in the Boyden chamber. f Activation of Ahr by TCDD (10 nmol/L) and DIM
(25 μmol/L) was confirmed by quantification of CYP1A1 gene expression by real-time PCR and western blot. Data are shown as mean ± SD of
three independent experiments performed in triplicates. b, c and f *; P < 0.05, significantly different from DMSO-treated control. d *; P < 0.05,
significantly different from siNS-transfected control. e significantly different from DMSO- and siNS-treated control
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regulated SOX4 in an Ahr-dependent fashion. In addition,
the role of SOX4 in mediating the inhibitory effects of
Ahr agonists on migration, expansion and invasion of
breast cancer cells was confirmed by over-expression of
SOX4. The TCDD- and DIM-mediated inhibition of
breast cancer cell migration, expansion and invasion
was moderately abrogated by SOX4 over-expression
(Additional file 1: Figure S4A and B).
The interaction of TCDD and DIM with SOX4 was fur-
ther analyzed by measuring the luciferase activity. The
MDA-MB-231 and T47D cells were transfected with 3′
UTR-SOX4-luc construct, which contains the candidate
binding sites for miR-212/132 cluster (MiRaNda v.21)
[32]. Activation of Ahr by TCDD and DIM decreased the
luciferase activities significantly, and these effects were re-
versed by co-transfection with as-miR-132 (Fig. 4c) and
as-miR-212 (Fig. 4d), suggesting a regulatory role of the
miRNA cluster on SOX4 gene expression.
SOX4 is a new target gene of miR-212/132 cluster in
breast cancer cells
An application of miRNA target scan algorithm, i.e., Mi-
RaNda [32], predicted that SOX4 is a candidate target
gene of the miR-212/132 cluster (Fig. 4e). To examine
this prediction, MDA-MB-231 and T47D cells were first
transfected with miR-212/132 mimics. Over-expression
of miR-212/132 in both cell lines decreased SOX4
mRNA (Additional file 1: Figure S5A and B). The cells
were also co-transfected with 3′UTR-SOX4-luc con-
struct and miR-212/132 mimics. As shown in Fig. 4f,
over-expression of miR-212/132 significantly decreased
the luciferase activity. These effects were abrogated
when the 3′UTR-SOX4-luc was replaced with a reporter
contains a mutated sequence where miR-212/132 seed
sequence binds (Fig. 4g). These results identified SOX4
as a new target gene of the miR-212/132 cluster in
MDA-MB-231 and T47D cells.
Fig. 3 MiR-212/132 cluster has a direct inhibitory role on motility of breast cancer cells in vitro. The role of miR-212/132 cluster on migration
of MDA-MB-231, expansion of T47D and invasion of breast cancer cells were examined by the transfection of miRNA mimics, miR-132 and miR-212, or
antisense, as-miR-132, as-miR-212. a Over-expression of the miR-212/132 cluster by mimics suppressed the migration of MDA-MB-231 and expansion of
T47D cells in wound healing assay compared with siNS-transfected control. b Mimics of the miR-212/132 cluster suppressed the invasion of MDA-MB-231
and T47D cells in the Boyden chamber assay. c Inhibition of miR-212/132 cluster by antisense partially blocked the inhibitory effects of TCDD and DIM on
invasion of MDA-MB-231 and T47D cells. d Efficiency of miR-212/132 knockdown by antisense compared with siNS was confirmed by real-time PCR. Data
are shown as mean ± SD of three independent experiments performed in triplicates. b and d *P < 0.05, significantly different from siNS-transfected
control. c *P < 0.05, significantly different as shown by lines
Hanieh Molecular Cancer  (2015) 14:172 Page 6 of 13
The suppressive effects of TCDD and DIM on metastasis of
breast cancer cells is concomitant with higher miR-212/132
expression
The effects of Ahr agonists on Ahr-miR-212/132-SOX4
module in vivo were tested using an established orthotopic
model of tumor growth and spontaneous metastasis.
Injection of MDA-MB-231 into the nipple fat pad of
athymic mice, and to a lesser extent T47D, resulted in
formation of primary tumor at the injection site and
pulmonary nodules that were adequate to represent
spontaneous metastasis (Additional file 1: Figure S6).
The TCDD at 25 μg/kg/day or DIM at 50 mg/kg/day
Fig. 4 TCDD and DIM suppress the pro-metastatic factor SOX4 by inducing the miR-212/132 cluster. a 10 nmol/L TCDD and 25 μmol/L DIM suppressed
SOX4 gene expression as quantified by real-time PCR and western blot. b Knockdown of Ahr by siAhr blocked the inhibitory effects of TCDD and DIM
on SOX4 compared with siNS-transfected MDA-MB-231 and T47D cells. c and d Co-transfection of 3′UTR-SOX4-luc and miRNA antisense, as-miR-132 or
as-miR-212, mitigated the inhibitory effects of TCDD and DIM on the luciferase activity in MDA-MB-231 and T47D. e SOX4 is a potential target gene of
the miR-212/132 cluster; complementary binding site of miR-212/132 on the SOX4 3′UTR. f Co-transfection of 3′UTR-SOX4-luc and miRNA
mimics, miR-132 or miR-212, suppressed the luciferase activity in MDA-MB-231 and T47D. g MiRNA mimics did not decrease the luciferase activity when
co-transfected with 3′UTR-SOX4-luc that contains mutated binding sites for miR-212/132. Data are shown as mean ± SD of three independent experiments
performed in triplicates. a *P < 0.05, significantly different from DMSO-treated control. b–d *P < 0.05, significantly different from the corresponding
DMSO- and siNS-treated control or Ahr agonist- and miRNA antisense treatments. f and g *P < 0.05, significantly different from siNS-transfected control
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was given orally for 10 days starting from the day of
breast cancer cell injection. The Ahr agonists treat-
ments did not show statistical significance on body and
lung weights compared with corn oil (Veh)-treated con-
trols (data not shown). Consistent with the in vitro re-
sults, treatment of T47D-injected mice with DIM
decreased the weight of the primary tumor that formed
at the injection site in 4 weeks (Fig. 5a). Interestingly,
the number of MDA-MB-231 pulmonary nodules was
less in Ahr agonists-treated mice compared with Veh-
treated control, whereas the number of T47D nodules
decreased with DIM treatment only (Fig. 5b).
To test whether Ahr agonists induce miR-212/132-SOX4
module in vivo, miRNA cluster and SOX4 mRNA were
quantified in the pulmonary nodules. TCDD, and to a
lesser extent DIM, significantly induced the expression of
miR-212/132 cluster in the isolated nodules of MDA-MB-
231- or T47D-injected mice (Fig. 5c). The SOX4 mRNA
was significantly down-regulated only in MDA-MB-231-
injected mice with the TCDD treatment. Although mean
values of SOX4 mRNA were less in other treatment groups
compared with Veh-treated controls, they did not reach
the level of significance (P < 0.05) as shown in Fig. 5d.
Discussion
The miRNAs are small non-coding RNAs that regulate
gene expression by complementary binding on the 3′
UTR of the target mRNA. Accumulating evidences have
demonstrated that miRNAs are involved in the progres-
sion or inhibition of different tumors including breast
cancer [33, 34]. In breast cancer, metastasis is a compli-
cated process that contributes to a high mortality rate
among other cancer patients [2]. It has been indicated
that miRNAs modulate metastasis of breast cancer cells
to different organs of the body [35, 36]. However, their
interaction with the transcription factors that play
prominent roles in breast cancer metastasis is rarely
investigated.
The Ahr has been extensively studied in different tu-
mors and cell lines of breast cancer, and now it is clear
that Ahr plays critical roles in modulating tumor progres-
sion [37, 38]. Current study showed that TCDD inhibited
invasion of MDA-MB-231 cells in vitro, whereas DIM
showed inhibitory effects on both cell lines. These results
were in a line with previous studies showed that TCDD
inhibited cell invasion in ER-negative breast cancer cell
lines in an Ahr-dependent fashion [25, 39]. The inhibitory
effects of DIM on cell invasion in ER-negative and ER-
positive cell line were also reported [40–42]. The in vivo
results showed that DIM, but not TCDD, decreased the
primary tumor weight that formed at the T47D injection
site. In contrast, previous studies showed that TCDD and
TCDD-related compounds inhibited mammary tumor
growth [43, 44]. These discrepancies were likely attributed
Fig. 5 TCDD and DIM suppress metastasis of breast cancer cells to the lungs and induce miR-212/132 in vivo. MDA-MB-231 or T47D were injected in
the fat pad of the second nipple of athymic nude mice. TCDD (25 μg/kg/day), DIM (50 mg/kg/day), or corn oil (Veh) were given orally for 10 days.
Non-transplanted (Neg) mice were used as negative controls. a DIM treatment decreased the weight of T47D primary tumor that formed at the breast
cancer cell injection site. b TCDD and DIM treatments decreased the number of pulmonary nodules in MDA-MB-231-injected mice, while the number
of the nodules in T47D-injected mice was decreased with DIM treatment. c TCDD and DIM induced the miR-212/132 expression in pulmonary nodules
of MDA-MB-231- or T47D-injected mice. d TCDD treatment suppressed SOX4 mRNA in the pulmonary nodules of MDA-MB-231-injected mice. Data are
shown as mean ± SD of three independent experiments. n = 8 in MDA-MB-231-injected mice. a–d *P < 0.05, significantly different from
Veh-treated control
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to the rodent model used, doses of Ahr agonists and the
number of these doses.
In previous studies, we demonstrated that activation of
Ahr by TCDD and FICZ induced the highly conserved
miR-212/132 cluster in murine cellular immune compart-
ment, and supporting results were obtained in Ahr−/− mice
[15, 30, 45]. Therefore, it was predicted in the current
study that Ahr agonists induce miR-212/132 in human
breast cancer cell lines, and these miRNAs may contribute
to the anti-tumor properties of these agonists. Activation
of Ahr by TCDD and DIM suppressed migration of MDA-
MB-231 and proliferation-based expansion of T47D cells,
and knockdown of Ahr reversed these effects. Inhibition of
miR-212/132 in Ahr-agonist treated cells mitigated the
anti-invasive effects of the agonists, and transfection with
mimics showed supporting results, suggesting that miR-
212/132 cluster mediated, at least partially, the anti-
invasive effects of TCDD and DIM. Also, these results indi-
cated an involvement of other molecules, probably other
miRNAs, in the anti-invasive effects of Ahr agonists.
MiR-212 and miR-132 are tandem miRNAs located in
an intergenic region on chromosome 17 in humans, and
they share the same seed sequence AACAGUCU. Ana-
lysis of the regulatory elements of the miR-212/132 gene
using online software, i.e., Promo V3.0.2 [31], revealed
the presence of two XRE boxes (GCGTG) located within
1 kb relative to the transcription site. A direct regulatory
role of Ahr on the miR-212/132 gene by association with
XRE boxes was tested by ChIP assay, and confirmed by
luciferase activity. The results identified a functional
XRE box, located at 830 bp from the transcription site,
on which Ahr was bound. Together, these results con-
firmed for the first time that Ahr directly regulated the
transcription of miR-212/132 gene.
The SOX4 transcription factor belongs to the SOX
(SRY-related HMG-box) family that is involved in em-
bryonic development and cell fate. It is demonstrated
that an inhibition of SOX4 is associated with a decreased
invasion and metastasis of breast cancer cells [46]. It is
also shown that TCDD and MCDF down-regulate SOX4
in MDA-MB-231 and BT474 by inducing miR-335 [25].
These effects are abrogated by Ahr knockdown and miti-
gated by miR-335 antisense in Ahr agonists-treated cells.
These results are in complement with those obtained in
the current study. Both TCDD and DIM reduced the lucif-
erase activity of the 3′UTR-SOX4 construct that contains
the predicted binding sites for the miR-212/132 cluster,
and mutation in these sites restored the luciferase activity.
Also, co-transfection of the 3′UTR-SOX4-luc and miR-
212/132 mimics or miRNA mimics alone showed support-
ing results. Taken together, the results identified SOX4 as
a new target gene of the miR-212/132 cluster in human
breast cancer cells. Notably, the effects of Ahr agonists on
SOX4 were repealed by Ahr knockdown and partially
reversed by miR-212/132 antisense in Ahr agonist-treated
cells, suggesting an involvement of other molecules, i.e.,
miRNAs, in the regulatory role of Ahr agonists on SOX4.
The involvement of Ahr-miR-212/132-SOX4 module
in the anti-metastatic properties of TCDD and DIM on
MDA-MB-231 and T47D were investigated in the pul-
monary nodules using a demonstrated model of spon-
taneous metastasis. Previous studies showed that oral
treatment of TCDD and DIM in breast cancer cells-
injected mice resulted in a reduction in the pulmonary
tumor nodules [24, 28]. These results were in line with
those obtained in the current study using MDA-MB-231
and T47D cells. Consistent with the in vitro results,
TCDD induced a reciprocal correlation between miR-
212/132 and SOX4 in vivo, which may explain, at least
partially, the anti-metastatic properties. The DIM treat-
ment induced miR-212/132 in vivo, to a lesser extent
compared with TCDD, and mean value of SOX4 did not
reach the significance level (P < 0.05). These differences
may be attributed to the agonists’ chemical structure.
TCDD contains four chlorine residues that give this agon-
ist stability and longer half-life, which attribute to strong
and sustained Ahr activation see [22].
Previous studies have suggested different mechanistic
explanations for the in vitro anti-invasive and the in
vivo anti-metastatic properties of Ahr agonists. For ex-
ample, TCDD and MCDF induce SOX4-targeting miR-
335 in MDA-MB-231 and BT474 cells in vitro [25]. It
has been also suggested that TCDD disrupt the CXCR4/
CXCL12 axis in an in vitro chemotaxis assay [47]. Oral
administration of DIM suppresses 4T1 metastasis to the
lungs by inhibition of two MMPs, adhesion molecules,
and pro-inflammatory cytokines [28]. Furthermore, dif-
ferent Ahr agonists show anti-estrogen effects by inhibi-
tory cross talk between Ahr and ER in ER-positive breast
cancer cells [48, 49]. In the current study, over-expression
of miR-212/132 showed anti-invasive properties, and in-
hibition of Ahr agonist-induced miRNA cluster abrogated
the agonists’ anti-invasive properties in MDA-MB-231
and T47D. These results suggest a new mechanism
through which miR-212/132 mediate the anti-metastatic
properties of TCDD and DIM by targeting the pro-
metastatic factor SOX4.
It has been shown that the constitutively active Ahr
enhances growth and motility of breast cancer cells by
different mechanisms such as transcription of breast
cancer gene 1 (BRCA1) oncogene and CYP1B1, and acti-
vation of epiregulin and Wnt signaling pathway see [50].
Therefore, inhibition of certain endogenous Ahr agonists
has suppressive effects on breast cancer progression.
This does not reflect contradiction with the inhibitory
properties of Ahr agonists, as agonists may force Ahr to
do different functions. For example, while endogenous
ligands enhance cancer by transcription of BRCA1
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oncogene, activation of Ahr by exogenous agonists sup-
press BRCA1 gene expression [51].
Conclusion
Taken together, the results not only provide a new
miRNA-based mechanism to understand the anti-
metastatic properties of Ahr agonists, but also provide
the first evidence of the synergistic anti-metastatic
properties of the members of miR-212/132 cluster in
human breast cancer cells, opening intriguing possibil-
ities of using this miRNA cluster as an innovative
therapeutic strategy for breast cancer.
Materials and methods
Cell culture
The human breast cancer cell lines MDA-MB-231 and
T47D were obtained from American Type Culture Collec-
tion (ATCC; Manassas, VA). The cells were maintained in
a complete medium contining Dulbecco’s modified Eagle’s
medium (DMEM)/Ham’s F12 nutrient mixture (F-12) at
1:1 (Sigma-Aldrich, St Louis, MO) supplemented with
10 % FBS and 1× of antibiotic antimycotic solution
(Gibco, Rockville, MD). Cells were incubated in a humidi-
fied atmosphere with 5 % CO2 at 37 °C.
Wound healing and invasion assays
Cells were seeded in 6-wells plate in a complete medium
for 24 h to attach. The cells were then treated with DMSO,
TCDD (Accustandard, New Haven, CT) or DIM (Sigma-
aldrich) for 24 h in 3 % charcoal-stripped FBS (Sigma-Al-
drich) DMEM/F-12. When cells reached 60–80 % conflu-
ent, a scratch was made at the axis of the well using
pipette tip, washed, and then treated again with DMSO or
Ahr agonists for another 24 h. The T47D medium was
supplemented with 10 nmol/L β-estradiol (E2; Santa
Cruz Biotechnology, Santa Cruz, CA). A 24-wells
matrigel coated Boyden chamber with 8.0 μm PET
membrane (Corning, New York, NY) was used for inva-
sion assay. The cells (2 × 104) were suspended in 200 μl
serum-free medium containing DMSO or Ahr agonists
and placed in the trans-well. The lower chamber con-
tained DMSO or Ahr agonists in 750 μl medium sup-
plement with 10 % FBS as an attractant. After 24 h,
cells were fixed by formaldehyde and permeabilized
with methanol, and then stained with Giemsa. Migrated
cells with spread-out shape were counted in 4 different
microscopic fields.
Cell proliferation and adhesion assays
4 × 104 MDA-MB-231 or T47D cells were seeded in 96-
well and incubated in 3 % charcoal-stripped FBS
DMEM/F-12 containing different concentration of Ahr
agonists for 48 h. Cell proliferation was quantified by
MTT assay using Cell-Counting Kit-8 (CCK-8; Dojindo,
Baltimor, MD) following manufacturer’s instructions. For
adhesion assay, 4 × 105 cells were seeded in 6-wells plate
and incubated overnight to adhere, then washed to re-
move non-adherent cells. Cells were then re-incubated
in charcoal-stripped medium containing DMSO or Ahr
agonists and incubated for 48 h. A single wash was per-
formed before examination.
Real-time PCR and western blot assays
Extracted RNA was reverse transcribed in a thermal cy-
cler using RT enzyme. The real-time PCR was carried
out in ViiA 7 system using TaqMan® gene expression as-
says. The cycling conditions were 50 °C for 2 min and
95 °C for 10 min, then 40 cycles of 95 °C for 15 s and
60 °C for 1 min. The comparative ΔΔCt method was ap-
plied to calculate fold change. For endogenous controls,
GAPDH was used for Ahr, CYP1A1 and SOX4, and
RNU6B was used for miR-212/132. System, reagents and
kits for real-time PCR were all from Applied Biosystems,
Grand Island, NY. For western blot, cell were lysed by
RIPA lysis buffer system (Santa Cruz Biotechnology), lysate
was then fractionated using SDS-PAGE system (Bio-Rad,
Richmond, CA). The Ahr, CYP1A1, SOX4 and β-actin
were detected using their rabbit polyclonal antibodies
(Santa Cruz Biotechnology). The intensities of the protein
bands were quantified via software [http://imagej.nih.gov/
ij/download.html] ImageJ v.1.48 [52].
ChIP assay
Analysis of the regulatory elements of the miR-212/132
gene was performed using transcription factor prediction
software [http://alggen.lsi.upc.es/] Promo V3.0.2 [31].
The ChIP assay was performed using ChiP-IT enzymatic
kit (Active Motif, Carlsbad, CA) following manufac-
turer’s instructions. Briefly, MDA-MB-231 and T47D
cells were treated with DMSO, TCDD or DIM for 24 h.
After that Ahr was immunopreciptated using specific
antibodies (Santa Cruz Biotechnology). Attached DNA
was prepared using proteinase K and further purified
using phenol/chloroform procedure. The PCR was done
using the following primer sets: XRE-1: forward 5′-CTCCT
TCTGCTCCGCGTC-3′, and reverse 5′-TCCGCGGTGC
TGATCAAC-3′; XRE-2: forward 5′-AGAGCACTACACC
CAGCAG-3′, and reverse 5′-CAGGTGTGAGACTTCCC
CAG-3′. The positive control CYP1A1 primers were used
as previously described [53]: forward 5′-TCAGGGCTGG
GGTCGCAGCGCTTCT-3′, and reverse 5′-GCTACAGC
CTACCAGGACTCGGCAG-3′.
Target gene prediction
Potential binding sites of miR-212/132 cluster (HGNC:3
1589/HGNC:31516) on the 3′UTR of SOX4 (HGNC:1
1200) were queried by the miRNA target prediction
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software microRNA.org [http://www.microrna.org] mi-
RaNda v.21 [32].
Cell transfection and luciferase reporter assays
The fragment of miR-212/132 promoter that contains
XRE-2 was cloned in the Xba1 restriction site of the basic
PGL-3 vector (Promega, Madison, WI) using the following
primers: forward 5′- AGATCGCCGTGTAATTCTAGAA
GAGCACTACACCCAGCAG-3′, and reverse 5′- GCCGG
CCGCCCCGACTCTAGACAGGTG TGAGACTTCCCC
AG-3′. The siAhr and siNS control (Ambion, Austin, TX)
were co-transfected with the miR-212/132 promoter re-
porter at the final concentration of 75 nmol/L. The 3′UTR-
SOX4-luc construct (SwitchGear Genomics, Menlo Park,
CA) was co-transfected with miR-212/132 mimics or anti-
sense (Ambion) at 250 nmol/L as previously described [45].
The binding specificity of miR-212/132 cluster on the
SOX4 3′UTR was examined by mutation in the sequence
on which miR-212/132 seed sequence bind (from
GACTGTT to GAGACGG). The MDA-MB-231 and
T47D cells were transfected using 4D-nucleofector device
and cell-specific transfection kits (Lonza, Walkersville,
MD). Cells were incubated for 6 h to recover, and then the
medium was changed. After 24 h, the cells were lysed and
luciferase activity was measured using luciferase reagents
(Promega).
Orthotopic model of spontaneous metastasis
Female BALB/c athymic nude mice, 6–8 weeks old were
purchased from King Faisal Specialist Hospital and Re-
search Center, Riyadh, KSA. The orthotopic model of
tumor growth and spontaneous metastasis was induced as
previously described using ER-negative and ER-positive
breast cancer cells [54]. The MDA-MB-231 and T47D
(2.5×105 cells) were suspended in 25 μl of serum-free
DMEM. The cells were injected directly into the fat pad of
the second left nipple through small incision. The mice re-
ceiving T47D cells were implanted with a 90-day release
E2 pellets (Innovative Research of America, Sarasota, FL).
Non-transplanted (Neg) mice were used as negative con-
trols. The TCDD at 25 μg/kg/day, DIM at 50 mg/kg/day
or corn oil were given orally for 10 consecutive days start-
ing from the breast cancer cell injection day. Visible sur-
face tumor nodules and internal nodules were excised
under dissection microscope directly after mice euthaniza-
tion. Lung samples from all mice were fixed in formalde-
hyde, sectioned to 5 μm thickness and stained with
conventional hematoxylin and eosin (H&E) for metastases
counting. All animals were maintained under specific
pathogen-free conditions and had free access to sterilized
feed and water. Animal experiments were performed in
accordance with the protocols approved by Animal Care
Committee of King Faisal University.
Statistics
Shown are mean ± SD of the results obtained from three
independent experiments studied in triplicates; n = 9 in
all experiments except when indicated. The significance
was analyzed by analysis of variance (ANOVA) test for
pooled data from all replicates. P < 0.05 was considered
significant.
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